DNA-adduct levels as a predictor of outcome for NSCLC patients receiving daily cisplatin and radiotherapy

International Journal of Cancer

Volumn 86, Issue 3, 2000, Pages 160-166

  Van De Vaart, Paul J M ^a,c   Belderbos, Jose ^a   De Jong, Daphne ^a   Sneeuw, Kommer C A ^b   Majoor, Donne ^a   Bartelink, Harry ^a   Begg, Adrian C ^a  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b Integraal Kankercentrum Amsterdam   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; KI 67 ANTIGEN; PROTEIN BCL 2; PROTEIN P53; ANTINEOPLASTIC AGENT; DNA; RADIOSENSITIZING AGENT;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CELL PROLIFERATION; CLINICAL ARTICLE; DNA ADDUCT; DNA MODIFICATION; FEMALE; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; TREATMENT OUTCOME; ANALYSIS OF VARIANCE; APOPTOSIS; CHEMISTRY; GENETICS; IMMUNOHISTOCHEMISTRY; LUNG TUMOR; MIDDLE AGED; MULTIMODALITY CANCER THERAPY; PREDICTION AND FORECASTING; PROPORTIONAL HAZARDS MODEL; RADIATION DOSE;

ADULT; AGED; ANALYSIS OF VARIANCE; ANTINEOPLASTIC AGENTS; APOPTOSIS; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; COMBINED MODALITY THERAPY; DNA ADDUCTS; DNA, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; LUNG NEOPLASMS; MALE; MIDDLE AGED; PREDICTIVE VALUE OF TESTS; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; PROTO-ONCOGENE PROTEINS C-BCL-2; RADIATION-SENSITIZING AGENTS; RADIOTHERAPY DOSAGE; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0034688940     PISSN: 00207136     EISSN: None     Source Type: Journal    
DOI: 10.1002/(sici)1097-0215(20000320)89:2<160::aid-ijc10>3.0.co;2-j     Document Type: Article

References (23)

1. BARTELINK, H., KALLMAN, R.F., RAPACCHIETTA, D. and HART, G.A., Therapeutic enhancement in mice by clinically relevant dose and fractionation schedules of cis-diamminedichloroplatinum (II) and irradiation. Radiother. Oncol., 6, 61-74 (1986).
2. BLUMMAERT, F.A., MICHAEL, C., TERHEGGEN, P.M.A.B., MUGGIA, F.M., KORTES, V., SCHORNAGEL, J.H., HART, A.A.M. and DEN ENGELSE, L., Drug-induced DNA modification in buccal cells of cancer patients receiving carboplatin and cisplatin combination chemotherapy, as determined by an immunocytochemical method: inter-individual variation and correlation with disease response. Cancer Res., 53, 5669-5675 (1993).
3. BOISK, L.H., GOTTSCHALK, A.R., QUINTANS, J. and THOMPSON, C.B., bcl-2 and bcl-2-related proteins in apoptosis regulation. Curr. Top. Microbiol. Immunobiol., 200, 107-121 (1995).
4. Du MANOIR, S., GUILLAUD, P., CAMEUS, E., SEIGNEURIN, D. and BRUGAL, G., Ki-67 labeling in post-mitotic cells defines different Ki-67 pathways within the 2c compartment. Cytometry, 12, 455-463 (1991).
5. FONTANINI, G., BIGINI, D., VIGNATI, S., MACCHIARINI, P., PEPE, S., ANGELETTI, C.A., PINGITORE, R. and SQUARTINI, F., p53 expression in non-small-cell lung cancer: clinical and biological correlations. Anticancer Res., 13, 737-742 (1993).
6. FUJINO, M., DOSAKA-AKITA, H., HARADA, M., HIROUMI, H., KINOSHITA, I., AKIE, K. and KAWAKAMI, Y., Prognostic significance of p53 and ras p21 expression in non-small-cell lung cancer. Cancer. 76, 2457-2463 (1995).
7. GATELY, D.P. and HOWELL, S.B., Cellular accumulation of the anti-cancer agent cisplatin: a review. Brit. J. Cancer, 67, 1171-1176 (1993).
8. GAVRIELI, Y., SHERMAN, Y. and BEN-SASSON, S.A., Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol., 119, 493-501 (1995).
9. HANSSON, J., EDGREN, M.R., EGYHAZI. S., HAO, X.Y., MANNERVIK, B. and RINGBORG, U., Increased cisplatin sensitivity of human Fibroblasts from a subject with inherent gluthathione deficiency. Acta oncol., 35, 683-690 (1996).
10. KOMAKI, R., MILAS, L., RO, J.Y., FUJII, T., PERKINS, P., ALLEN, P., SIKES, C.R., MOUNTAIN, C.F. and ORDONEZ, N.G., Prognostic biomarker study in pathologically staged N1 non-small-cell lung cancer. Int. J. Radiat. Oncol. Biol. Phys., 40, 787-796 (1998).
11. KOMAKI, R., SCOTT, C.B., LEE, J.S., URTASUN, R.C., BYHARDT, R.W., EMAMI, B., ANDRAS, E.J., ASBELL, S.O., ROTMAN, M. and Cox, J.D., Impact of adding concurrent chemotherapy to hyperfractionated radiotherapy for locally advanced non-small-cell lung cancer (NSCLC); comparison of RTOG 83-11 and RTOG 91-06. Amer. J. Clin. Oncol., 20, 435-440 (1997).
12. LOWE, S.W., SCHMITT, E.M., SMITH, S.W. and JACKS, T., p53 is required for radiation-induced apoptosis in mouse thymocytes. Nature (Lond.), 362, 847-849 (1993).
13. MURRAY, D., PRAGER, A., MEYN, R.E., DAVISON, S. and GREEN, A.D., Relationships between DNA damage and the survival of radiosensitive mutant Chinese hamster cell lines exposed to gamma radiation; part 2: effect of cellular redox status. Int. J. Radiat. Biol., 63, 199-206 (1993).
14. ROSE, P.G., BUNDY, B.N., WATKINS, E.B., THIGPEN, J.T., DEPPE, G., MAIMAN, M.A., CLARKE-PEARSON, D.L. and INSALACO, S., Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer. New Engl. J. Med. 340, 1144-1153 (1999).
15. RUSCH, V., KLIMSTRA, D., VENKATRAMAN, E., OLIVER, J., MARTINI, N., GRALLE, R., KRIS, M.G. and DMITROVSKY, E., Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small-cell lung cancer. Cancer Res., 55, 5038-5042 (1995).
16. SAUNDERS, M.I., DISCHE, S., BARRETT, A., HARVEY, A., GIBSON, D. and PARMER, M., Continuous hyperfractionated accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small-cell lung cancer: a randomised multicentre trial. Lancet, 350, 161-165 (1997).
17. SCHAAKE-KONING, C., SCHUSTER-UITTERHOEVE, L., HART, G. and GONZALEZ-GONZALEZ, D., Prognostic factors of inoperable localized lung cancer treated by high-dose radiotherapy. Int. J. Radiat. Oncol. Biol. Phys., 9, 1023-1028 (1983).
18. SCHAAKE-KONING, C. and 15 OTHERS, Effects of concomitant cisplatin and radiotherapy on inoperable non-small-cell lung cancer. New Engl. J. Med., 326, 524-530 (1992).
19. SCHELLENS, J.H., MA, J., PLANTING, A.S.T., VAN DER BURG, M.E., VAN MEERTEN, E., DE BOER-DENNERT, M., SCHMITZ, P.I.M., STOTER, G. and VERWEIJ, J., Relation between the exposure to cisplatin, DNA-adduct formation in leucocytes and tumour response in patients with solid tumours. Brit. J. Cancer, 73, 1569-1575 (1996).
20. SCHUSTER-UITTERHOEVE, L., VAN DE VAART, P.J.M., SCHAAKE-KONING, C., BENRAADT, J., KOOLEN, M.G.J., GONZALEZ-GONZALEZ, D. and BARTELINK, H., Feasibility of escalating daily doses of cisplatin in combination with accelerated radiotherapy in non-small-cell lung cancer. Europ. J. Cancer, 32A, 1314-1319 (1996).
21. SHELLARD, S.A., HOSKING, L.K. and HILL, B.T., Anomalous relationship between cisplatin sensitivity and the formation and removal of platinum-DNA adducts in two human ovarian-carcinoma cell lines in vitro. Cancer Res., 51, 4557-4564 (1991).
22. TERHEOOEN, P.M.A.B., EMONDT, J.Y., FLOOT, B.G.J., DUKMAN, R., SCHIER, P.I., DEN ENOELSE, L. and BEGG, A.C., The correlation between cell killing by cisplatinum in six mammalian cell lines and binding of a cisplatinum-DNA anti-serum. Cancer Res., 50, 3556-3561 (1990).
23. VAN DE VAART, P.J.M., KLAREN, H.M., HOFLAND, I. and BEGG, A.C., The oral platinum analogue JM216 is a radiosensitiser in oxic murine cells. Int. J. Radiat. Biol., 72, 675-683 (1997).